The Value Based Contract Impact Assessment Model (VBCAM) is an open-access tool developed to facilitate the planning of value-based contracts (VBCs) for cell and gene therapies and other novel therapies. VBCAM can be used during risk identification and financial planning before contracting parties enter into an agreement for a new clinical product. VBCAM incorporates the efficacy estimates from the product’s clinical trials alongside performance values that reflect the payer’s beliefs about the product’s real-world performance.

This hypothetical case for use for VBCAM illustrates its role in the development of a value-based contract for a sickle cell gene therapy. The expected outcome is the absence of hospitalizations due to vascular-occlusion events (VOEs) for 24 months post-infusion. In the use-case clinical trial, 34 of 39 individuals (87.1%) had a complete absence of hospitalization due to VOEs 24 months post infusion. The use case assumes the same coverage criteria under all scenarios.